

4th August, 2023

To,
The Manager - Corporate Relationship Dept.
BSE Limited

P. J. Towers, Dalal Street Fort, Mumbai - 400 001 To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

Scrip Code: BSE - 524500

Scrip Code: NSE - KILITCH

Sub: Intimation of the Board Meeting to consider the Financial Results for the quarter ended 30th June, 2023

Dear Sir,

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the meeting of the Board of Directors of the Company will be held on Friday, 11<sup>th</sup> August, 2023 inter-alia to consider and approve the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30<sup>th</sup> June, 2023.

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2<sup>nd</sup> April, 2019 issued by BSE and Circular Reference no. NSE/CML/2019/11 dated 2<sup>nd</sup> April, 2019 issued by NSE and Company's code of conduct for Prevention of Insider Trading, the Trading Window has been closed with effect from 1<sup>st</sup> July, 2023 and will re-open 48 hours after said financial results are disclosed to the Stock Exchanges.

We request you to kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For Kilitch Drugs (India) Limited

Mukund Mehta Managing Director DIN: 00147876







